Virginia has enacted legislation to swiftly allow the medical use of psilocybin, the active compound in psychedelic mushrooms, once a formulation receives approval from the U.S. Food and Drug Administration. The move prepares the state's healthcare system to integrate the potential treatment for conditions like severe depression and PTSD, particularly for veterans.
The new law, Senate Bill 379, directs the state Board of Pharmacy to reschedule psilocybin from a Schedule I substance to a level consistent with federal classification upon FDA approval. This legal mechanism is designed specifically for clinical use and does not address decriminalization for recreational purposes. The bill's sponsor, State Senator Jennifer Boysko, emphasized its intent as a proactive solution, citing promising clinical research and personal motivation following a loss to suicide. "If we have a treatment available that could help, I think we should do it," Boysko said. The legislation passed with unanimous, bipartisan support.
The push is heavily supported by veterans' groups, given the high rates of suicide and mental health challenges within that community. With over 678,000 veterans residing in Virginia, organizations like the Veterans of Foreign Wars Department of Virginia lobbied for the bill. "The staggering numbers of veteran suicide demands that we urgently provide access to solutions that are approved at the FDA level," said VFW representative David Jones. Research indicates a significant need, with diagnosed depression cases among service members increasing after deployments.
This legislative preparation coincides with advanced clinical trials for synthetic psilocybin formulations. Biotechnology company Compass Pathways is in late-stage trials for its COMP360 psilocybin treatment for treatment-resistant depression. In studies, a 25-milligram dose led to a 25% to 39% reduction in depression symptoms. The company has completed a key Phase 3 trial and has requested a meeting with the FDA. Former Virginia senator and current Lieutenant Governor Ghazala Hashmi, who previously sponsored similar legislation, stated the advanced preparation will allow Virginians to access treatment "legally and without delay" upon federal approval.
The path forward is now contingent on federal action. If the FDA approves a psilocybin-based therapy like COMP360, a federal rescheduling would trigger Virginia's new law, enabling prescriptions. Nationally, a bipartisan bill in Congress, the Innovative Therapies Centers of Excellence Act, proposes designating VA facilities for therapies including psilocybin. For many patients and advocates in Virginia, the state's preparatory law represents a critical and hopeful step toward addressing mental health crises with novel, evidence-based treatments.